The U.S. Food and Drug Administration cleared Qiagen’s QiaStat‑Dx Gastrointestinal Panels for the QiaStat‑Dx Rise automated, high‑throughput molecular testing platform. Laboratories can now run both respiratory and GI panels on a single Rise instrument, yielding results in about one hour with minimal hands‑on time. The cleared GI panels detect a broad panel of bacterial, viral and parasitic pathogens, including clinically relevant STEC subtypes; the system reports Ct values and amplification curves for co‑infection context. The clearance expands automated syndromic testing capacity at a time when rapid, multiplex diagnostics remain central for hospital and public health response.